Pharmacogenomics of serious adverse drug reactions in pediatric oncology

Colin J.D. Ross, Henk Visscher, S. Rod Rassekh, Lucila I. Castro-Pastrana, Evan Shereck, Bruce Carleton, Michael R. Hayden

Research output: Contribution to journalReview articlepeer-review

31 Scopus citations


Adverse drug reactions (ADRs) rank as one of the top ten leading causes of death and illness in the developed world. In cancer therapy, more patients are surviving cancer than ever before, but 40% of cancer survivors suffer life-threatening or permanently disabling severe ADRs and are left with long-term sequelae. ADRs are often more frequent and more severe in children, and the consequences for children who experience a severe ADR can be catastrophic. Pharmacogenomics has the potential to improve the safety of these drugs. This review highlights severe ADRs that can occur in cancer therapy that are more frequent and more severe in children, and the pharmacogenomics research that aims to understand, predict, and ultimately prevent these severe reactions.

Original languageEnglish (US)
Pages (from-to)e134-e151
JournalJournal of Population Therapeutics and Clinical Pharmacology
Issue number1
StatePublished - 2011
Externally publishedYes


  • Adverse drug reactions
  • Oncology
  • Pediatric
  • Pharmacogenomics

ASJC Scopus subject areas

  • Health Policy
  • Pharmacology (medical)


Dive into the research topics of 'Pharmacogenomics of serious adverse drug reactions in pediatric oncology'. Together they form a unique fingerprint.

Cite this